Skip to main content
OpenTrials

Clinical trial condition

Histiocytosis

Explore clinical trials studying Histiocytosis. Study availability and eligibility vary by location and protocol.

406 public trials 82 recruiting studies
Refine in advanced search Browse all conditions

Histiocytosis trial results

Active, not recruiting

Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH

NCT07204041

Conditions
Hemic and Lymphatic Diseases, Histiocytosis, Histiocytosis, Langerhans-Cell, +5 more
Locations
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing, Beijing, China
View Trial Details
Active, not recruiting

An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

NCT06734078

Conditions
DLBCL - Diffuse Large B Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +5 more
Locations
  • IRCCS Azienda Ospedaliero - Universitaria di Bologna Bologna, Italy
  • Casa Sollievo della Sofferenza - Reparto di Oncoematologia San Giovanni Rotondo, Foggia, Italy
  • Azienda Ospedaliera Universitaria- Policlinico di Bari Bari, Italy
  • Ospedale Oncologico Armando Businco Cagliari, Italy
View Trial Details
Active, not recruiting

Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT03064867

Conditions
Dendritic Cell Sarcoma, Interdigitating, Diffuse Large B-cell-lymphoma, Hemic and Lymphatic Diseases, +5 more
Locations
  • Washington University School of Medicine, Siteman Cancer Center St Louis, Missouri, United States
  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
View Trial Details
Completed

DPX-Survivac and Checkpoint Inhibitor in DLBCL

NCT03349450

Conditions
Adult Diffuse Large Cell Lymphoma, Adult Refractory Diffuse Large B-Cell Lymphoma, Dendritic Cell Sarcoma, Interdigitating, +18 more
Locations
  • Tom Baker Cancer Centre - Alberta Health Services Calgary, Alberta, Canada
  • Nova Scotia Health Authority: Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia, Canada
  • London Health Sciences Centre London, Ontario, Canada
  • Ottawa Hospital Research Institute Ottawa, Ontario, Canada
View Trial Details

Related conditions